Looking to bolster its capabilities in interventional portfolio and provide a strong return for investors, Boston Scientific (NYSE:BSX) has agreed to a £3.3B cash deal to buy Britain's BTG (OTCPK:BTGGF).
BTG, which has long produced drugs to treat overdoses and rattlesnake bites, has focused on interventional medicine - using devices to deliver drugs to affected organs - in recent years, for example producing beads that target tumors.
The transaction is expected to be two to three cents accretive to Boston Scientific adjusted earnings per share in 2019, and increasingly accretive thereafter.
